Manish Kohli1, Ann L Oberg2, Douglas W Mahoney2, Shaun M Riska2, Robert Sherwood3, Yuzi Zhang2, Roman M Zenka4, Deepak Sahasrabudhe5, Rui Qin6, Sheng Zhang7. 1. Department of Medical Oncology, Mayo Clinic, Rochester, MN. Electronic address: Manish.Kohli@moffitt.org. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 3. Institute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY. 4. Proteomcis Core, Mayo Clinic, Rochester, MN. 5. Department of Medicine, University of Rochester, NY. 6. Clinical Biostatistics, Janssen Pharmaceuticals, Raritan, NJ. 7. Institute for Biotechnology and Life Science Technologies, Cornell University, Ithaca, NY. Electronic address: sz14@cornell.edu.
Abstract
BACKGROUND: We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1) untreated "paired" pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2) "early ADT failure" patients (n = 10) in whom ADT treatment failed within a short period of time; and (3) "late ADT failure" patients (n = 10) in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA) was used to identify interaction networks in selected candidates from these comparisons. RESULTS: Between "post-ADT" and combined "early" and "late" ADT failure groups 149 differentially detected candidates were observed, and between "early" and "late" ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P < .01) including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. CONCLUSION: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.
BACKGROUND: We investigated the serum proteome of hormone-sensitive prostate cancerpatients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS: Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using reverse-phase liquid chromatography coupled to tandem mass spectrometry. The advanced hormone-sensitive prostate cancer cohorts studied were: (1) untreated "paired" pre-ADT and 4-month post-ADT hormone-sensitive patients (n = 15); (2) "early ADT failure" patients (n = 10) in whom ADT treatment failed within a short period of time; and (3) "late ADT failure" patients (n = 10) in whom ADT treatment failed after a prolonged response time. Differential abundance was assessed, and ingenuity pathway analysis (IPA) was used to identify interaction networks in selected candidates from these comparisons. RESULTS: Between "post-ADT" and combined "early" and "late" ADT failure groups 149 differentially detected candidates were observed, and between "early" and "late" ADT failure groups 98 candidates were observed; 47 candidates were common in both comparisons. IPA network enrichment analysis of the 47 candidates identified 3 interaction networks (P < .01) including 17-β-estradiol, nuclear factor kappa-light-chain enhancer of activated B cells complex, and P38 mitogen-activated protein kinases as pathways with potential markers of response to ADT. CONCLUSION: A global proteomic analysis identified pathways with markers of ADT response, which will need validation in independent data sets.
Authors: Junmin Peng; Joshua E Elias; Carson C Thoreen; Larry J Licklider; Steven P Gygi Journal: J Proteome Res Date: 2003 Jan-Feb Impact factor: 4.466
Authors: Philip L Ross; Yulin N Huang; Jason N Marchese; Brian Williamson; Kenneth Parker; Stephen Hattan; Nikita Khainovski; Sasi Pillai; Subhakar Dey; Scott Daniels; Subhasish Purkayastha; Peter Juhasz; Stephen Martin; Michael Bartlet-Jones; Feng He; Allan Jacobson; Darryl J Pappin Journal: Mol Cell Proteomics Date: 2004-09-22 Impact factor: 5.911
Authors: Robert W Ross; Wanling Xie; Meredith M Regan; Mark Pomerantz; Mari Nakabayashi; Timothy J Daskivich; Oliver Sartor; Mary-Ellen Taplin; Philip W Kantoff; William K Oh Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe Journal: N Engl J Med Date: 1998-10-08 Impact factor: 91.245
Authors: Amanda Khoo; Lydia Y Liu; Julius O Nyalwidhe; O John Semmes; Danny Vesprini; Michelle R Downes; Paul C Boutros; Stanley K Liu; Thomas Kislinger Journal: Nat Rev Urol Date: 2021-08-27 Impact factor: 14.432
Authors: Lauren K Jillson; Gabriel A Yette; Teemu D Laajala; Wayne D Tilley; James C Costello; Scott D Cramer Journal: Cancers (Basel) Date: 2021-06-30 Impact factor: 6.639